Fineline Cube

Follow:
14475 Articles
Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine
CompanyMedical Device

Medtronic’s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine

CompanyMedical Device

Jenscare Completes First-in-Human Study of iJensRobo Robot-Assisted Tricuspid Valve Replacement System

CompanyDrug

Clover Biopharmaceuticals Completes Enrollment in Phase II Trial of Trimer-Tag Respiratory Combination Vaccines for Older Adults

J&J’s Darzalex SC Becomes First Oncology Injectable in Europe Approved for Patient Self-Administration
CompanyDrug

J&J’s Darzalex SC Becomes First Oncology Injectable in Europe Approved for Patient Self-Administration

CompanyDeals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

CompanyDrug

GSK’s Bepirovirsen Receives EMA Review Acceptance for Chronic Hepatitis B, Pioneering Triple-Mechanism ASO Therapy

CompanyDrug

AstraZeneca’s Tozorakimab Reduces COPD Exacerbations in Phase III Trials, Targeting IL-33 in First-in-Class Approach

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety
CompanyDrug

J&J’s Icotyde Sustains and Improves Complete Skin Clearance in Psoriasis Through 52 Weeks, Outperforming Deucravacitinib on Safety

CompanyDrug

Takeda’s Zasocitinib Demonstrates Superior Efficacy Over Apremilast and Placebo in Phase III Psoriasis Trials with Unprecedented TYK2 Selectivity

CompanyDeals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets
CompanyDeals

Sinovac Biotech and Indonesia’s Bio Farma Forge Strategic Alliance to Expand Vaccine Access Across Developing Markets

RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin
Company

RemeGen Posts 89% Revenue Surge in 2025, Returns to Profitability on Strength of Tai’ai and Disitamab Vedotin